Johnson & Johnson Beats Earnings Estimates Despite Light Revenues
By Zacks Investment Research on April 14, 2009 | More Posts By Zacks Investment Research | Author's Website
This morning Johnson & Johnson, Inc. (JNJ) reported financial results for the first quarter ending March 31, 2009.
Revenue for the quarter came in at $15.0 billion, about $521 million below our forecast and down 7.2% from the same period in 2008. Revenue was negatively impacted by 6% due to foreign exchange, while operational results fell by 1.2%. Consumer, Pharmaceutical and Medical Devices sales contracted by 8.7%, 10.1% and 2.9%, respectively, compared to the same period in 2008.
Consumer sales fell 1.0% operationally and 7.7% due to foreign exchange. Strong sales of Listerine, Neutrogena and Aveeno were offset by significant weakness in the OTC/Nutritionals segment. Pharmaceutical division sales fell 5.0% operationally and 5.1% due to foreign exchange.
Pharmaceutical results were largely inline with our expectations, with Concerta posting strong year-over-year growth while Risperdal and Procrit sales fell at an accelerated rate in the period. Medical Devices sales grew 3.1% operationally which was more than offset by 6.0% due to foreign exchange. Medical Devices results were impacted by significantly softer sales of diabetes/glucose monitoring test strips as consumers cut back on out-of-pocket purchases.
Despite the revenue shortfall, EPS on an adjusted basis was $1.26, compared to our forecast of $1.20. Earnings exceeded expectations due to significantly lower than forecasted SG&A and R&D spend in the quarter a well as stronger gross margin due to the affects of foreign exchange.
Management affirmed previously issued full-year 2009 EPS guidance of $4.45 - $4.55, excluding special items.
Ron Paul Thinks That Fed “Oversight Is Laughable”
S&P 500 Index Is Still Overvalued
This Small Oil Exploration Company Is Ripe For A Takeover… Here’s How To Profit
Obama Commits To Free Trade Agreement With South Korea, But Auto Trade Remains An Obstacle
Exponential Growth, Finite World
Bay Street Stocks Slip Slightly Again - Canadian Commentary - 1 day ago
Stocks Close Mostly Lower Amid Disappointing Quarterly Results - U.S. Commentary - 1 day ago
Bay Street Stocks Linger Slightly Below Unchanged Level - Canadian Commentary - 1 day ago
Stocks Remain Stuck In The Red In Mid-Afternoon Trading - U.S Commentary - 1 day ago
European Markets Fall, Led By Banks, Oils - European Commentary - 1 day ago


